NOV 12, 2020 12:00 PM PST

Measuring levels of neutralizing antibodies in SARS CoV-2 infected/recovered and vaccinated individuals using a high-throughput and cost-effective test

Sponsored by: GenScript
C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Field Application Scientist Manager, North America, GenScript USA, Inc.
    Biography

      Sean Taylor holds a Ph.D. and an MBA from McGill University and has spent the past ten years publishing articles, providing seminars, workshops and training videos to help the global scientific community achieve excellent data from western blotting, qPCR and digital PCR experiments. He has managed teams of Field Application Scientists (FAS) in Canada for over a decade who have helped thousands of scientists achieve their research goals. In his current role as North American FAS Manager for GenScript, he leads a dedicated team to continue the tradition of providing pertinent and timely information to help the scientific community overcome research hurdles to accelerate the production of high quality, publishable data, cost-effectively.


    Abstract

    As many parts of the northern hemisphere move into the colder months and indoors, SARS CoV-2 has begun a second infection wave that has exceeded the first surge of cases in many global regions. This will likely be complicated by the upcoming flu season and underlines the requirement for effective testing to specifically assess and quantify the protective neutralizing antibody response post SARS CoV-2 infection or vaccination. The quantification of differential immune response levels and longevity between individuals for large populations remains elusive and constrained by the current neutralizing antibody test methods that require live cells and virus with tedious, costly and time consuming procedures. A newly available assay termed cPass SARS-Cov-2 Virus Neutralization Test (also known as Surrogate Virus Neutralization assay) permits the quantitative evaluation of protective neutralizing antibodies in a simple, cost-effective and high-throughput test amenable that mirrors the data from live cell assays. Samples from SARS CoV-2 recovered individuals exhibited differences up to 400-fold in neutralizing antibody titers raising questions around the: 1) strength of immune response between both infected and vaccinated individuals; 2) level of protection against re-infection and 3) duration of protection post infection/vaccination. All of which can be answered using the cPassTM sVNT.

    Learning Objectives:

    1. Brief overview of SARS CoV-2 infection mechanism

    2. Description of cPassTM sVNT, its advantages and comparative qualitative data with live cell neutralization and serology tests

    3. Quantitative protocol for cPassTM sVNT and its application to samples from recovered SARS CoV-2 individuals


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    AUG 25, 2020 8:00 AM PDT
    C.E. CREDITS
    AUG 25, 2020 8:00 AM PDT
    DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
    DEC 15, 2020 10:00 AM PST
    C.E. CREDITS
    DEC 15, 2020 10:00 AM PST
    DATE: December 15, 2020 TIME: 10:00am PST Scientists from Thermo Fisher Scientific will walk us through the world of microorganisms. They will discuss their most recent research on viruses,...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    Loading Comments...
    Show Resources